Isolation and Characterization of Urinary Extracellular Vesicles from Healthy Donors and Patients with Castration-Resistant Prostate Cancer

被引:14
|
作者
Lee, Haneul [1 ]
Kang, Su Jin [1 ]
Lee, Jimin [2 ]
Park, Kyong Hwa [2 ]
Rhee, Won Jong [1 ,3 ,4 ]
机构
[1] Incheon Natl Univ, Dept Bioengn & Nanobioengn, Incheon 22012, South Korea
[2] Korea Univ, Dept Internal Med, Div Oncol Hematol, Coll Med, Seoul 02841, South Korea
[3] Incheon Natl Univ, Div Bioengn, Incheon 22012, South Korea
[4] Incheon Natl Univ, Res Ctr Bio Mat & Proc Dev, Incheon 22012, South Korea
基金
新加坡国家研究基金会;
关键词
liquid biopsy; extracellular vesicle; prognosis; urine; castration-resistant prostate cancer; MICRORNA BIOMARKERS; PROGRESSION; MIRNAS;
D O I
10.3390/ijms23137134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men in developed countries. The five-year survival rate for men diagnosed with early-stage PCa is approximately 100%, while it is less than 30% for castration-resistant PCa (CRPC). Currently, the detection of prostate-specific antigens as biomarkers for the prognosis of CRPC is criticized because of its low accuracy, high invasiveness, and high false-positive rate. Therefore, it is important to identify new biomarkers for prediction of CRPC progression. Extracellular vesicles (EVs) derived from tumors have been highlighted as potential markers for cancer diagnosis and prognosis. Specifically, urinary EVs directly reflect changes in the pathophysiological conditions of the urogenital system because it is exposed to prostatic secretions. Thus, detecting biomarkers in urinary EVs provides a promising approach for performing an accurate and non-invasive liquid biopsy for CPRC. In this study, we effectively isolated urinary EVs with low protein impurities using size-exclusion chromatography combined with ultrafiltration. After EV isolation and characterization, we evaluated the miRNAs in urinary EVs from healthy donors and patients with CRPC. The results indicated that miRNAs (miR-21-5p, miR-574-3p, and miR-6880-5p) could be used as potential biomarkers for the prognosis of CRPC. This analysis of urinary EVs contributes to the fast and convenient prognosis of diseases, including CRPC, in the clinical setting.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Role of extracellular vesicles in castration-resistant prostate cancer
    Liao, Chaoyu
    Huang, Zeyu
    Liu, Jingui
    Deng, Min
    Wang, Leyi
    Chen, Yutong
    Li, Jia
    Zhao, Jiang
    Luo, Xing
    Zhu, Jingzhen
    Wu, Qingjian
    Fu, Weihua
    Sun, Bishao
    Zheng, Ji
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 197
  • [2] Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones
    Leung, Jacky K.
    Tam, Teresa
    Wang, Jun
    Sadar, Marianne D.
    HUMAN CELL, 2021, 34 (01) : 211 - 218
  • [3] Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones
    Jacky K. Leung
    Teresa Tam
    Jun Wang
    Marianne D. Sadar
    Human Cell, 2021, 34 : 211 - 218
  • [4] Enzalutamide for Patients with castration-resistant Prostate Cancer
    Kessing, Richard
    AKTUELLE UROLOGIE, 2020, 51 (01)
  • [5] Cabazitaxel in patients with castration-resistant prostate cancer
    Falcao, Gil
    Carneiro, Cabrita
    Pinheiro, Luis Campos
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 25 - 25
  • [6] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [7] Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
    Isebia, Khrystany T.
    Dathathri, Eshwari
    Verschoor, Noortje
    Nanou, Afroditi
    De Jong, Anouk C.
    Coumans, Frank A. W.
    Terstappen, Leon W. M. M.
    Kraan, Jaco
    Martens, John W. M.
    Bansal, Ruchi
    Lolkema, Martijn P.
    CANCERS, 2022, 14 (18)
  • [8] Apalutamide for the treatment of patients with castration-resistant prostate cancer
    Hauke, R.
    DRUGS OF TODAY, 2018, 54 (10) : 585 - 590
  • [9] Enzalutamide for Patients with castration-resistant Prostate Cancer Comment
    Kretschmer, Alexander
    AKTUELLE UROLOGIE, 2020, 51 (01)
  • [10] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876